The association between receptor binding affinity and metabolic side effect profile of antipsychotics and major cardio- and cerebrovascular events: A case/non-case study using VigiBase

•APs with high affinity for Adrenergic alfa-1, Histaminic H1, Muscarinic M1, and Serotoninergic 5-HT2A were associated with a higher risk of reporting of MACCE compared to low affinity.•MACCE reporting rates might be related to those receptors antagonism as ziprasidone, olanzapine, and clozapine pre...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European neuropsychopharmacology 2020-06, Vol.35, p.30-38
Hauptverfasser: Aguiar, João Pedro, Alves da Costa, Filipa, Egberts, Toine, Leufkens, Hubert, Souverein, Patrick
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 38
container_issue
container_start_page 30
container_title European neuropsychopharmacology
container_volume 35
creator Aguiar, João Pedro
Alves da Costa, Filipa
Egberts, Toine
Leufkens, Hubert
Souverein, Patrick
description •APs with high affinity for Adrenergic alfa-1, Histaminic H1, Muscarinic M1, and Serotoninergic 5-HT2A were associated with a higher risk of reporting of MACCE compared to low affinity.•MACCE reporting rates might be related to those receptors antagonism as ziprasidone, olanzapine, and clozapine presented the highest RORs.•APs with higher-risk of MSE were associated with higher risk of reporting of MACCE compared to the lower-risk. Antipsychotics (APs) have been associated with major adverse cardio- and cerebrovascular events (MACCE), but the underlying mechanisms are unclear. Our aim was to elucidate the association between APs, stratified for receptor affinity and metabolic side effects (MSE), in the reporting of MACCE. A case/non-case study was conducted using data from the WHO global Individual Case Safety Report (ICSR) database, VigiBase, among all reports associated with an AP. Cases were ICSRs of MACCE, while non-cases were all other adverse drug reactions (ADRs). APs were classified by AP group, the degree of receptor affinity for adrenergic, dopaminergic, muscarinic, histaminic, and serotoninergic receptors and by MSE profile. The strength of the association was estimated with logistic regression and expressed as crude and adjusted reporting odds ratios (RORadj.) with corresponding 95% confidence intervals (95%CIs). We identified 4987 reports of MACCE and 328,907 reports of other ADRs. Atypical APs (RORadj. 2.46; 95%CI 2.20–2.74) were significantly associated with the reporting of MACCE compared to typical ones. APs with high affinity for Adrenergic alfa-1 (RORadj. 2.98; 95%CI 1.93–4.59), Histaminic H1 (RORadj. 2.31; 95%CI 1.98–2.68), Muscarinic M1 (RORadj. 1.87; 95%CI 1.74–2.01), and Serotoninergic 5-HT2A (RORadj. 3.19; 95%CI 2.07–4.92) were associated with a higher risk of reporting of MACCE compared to low affinity. APs with higher-risk of MSE were associated with higher risk of reporting of MACCE (RORadj. 1.88; 95%CI 1.73–2.05) compared to the lower-risk. APs with high affinity for Adrenergic alfa-1, Histaminic H1, Muscarinic M1, and Serotoninergic 5-HT2A receptors and with high-risk of MSE may explain the occurrence of those events.
doi_str_mv 10.1016/j.euroneuro.2020.03.022
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2404046306</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0924977X20300973</els_id><sourcerecordid>2404046306</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-dff7f3aaed0779e28106e6c7ec79d08481fa6cac96aa9cb5772d47623b4ea0ef3</originalsourceid><addsrcrecordid>eNqFkVFvFCEQx4nR2Gv1KyiPvuyWhS3c-nY2ak2a-FKNb4SFoZ3LHpzAnrlv5seT9WpfDQlMht9_huFPyNuOtR3r5OW2hTnFsGwtZ5y1TLSM82dk1a2VaNRa8udkxQbeN4NSP87Iec5bxrorIYaX5Ezwvt5JtiK_7x6AmpyjRVMwBjpC-QUQaAIL-xITHTE4DPfUeI8By5Ga4OgOihnjhJZmdEDBe7CF7lP0OAGNvkIF9_loH2JBm08as63lrEkOY_M3YyHBmOLBZDtPJlE4QCj5Pd1UKsNliKFZAprL7I50zsszvuM9fqjJV-SFN1OG14_nBfn26ePd9U1z-_Xzl-vNbWN7zkrjvFdeGAOOKTUAX3dMgrQKrBocW_frzhtpjR2kMYMdr5TirleSi7EHw8CLC_LuVLcO93OGXPQOs4VpMgHinHX9ybqkYLKi6oTaFHNO4PU-4c6ko-6YXmzTW_1km15s00zoaltVvnlsMo87cE-6fz5VYHMCoI56QEg6W4RgwWE1qmgX8b9N_gBt87Nj</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2404046306</pqid></control><display><type>article</type><title>The association between receptor binding affinity and metabolic side effect profile of antipsychotics and major cardio- and cerebrovascular events: A case/non-case study using VigiBase</title><source>Elsevier ScienceDirect Journals</source><creator>Aguiar, João Pedro ; Alves da Costa, Filipa ; Egberts, Toine ; Leufkens, Hubert ; Souverein, Patrick</creator><creatorcontrib>Aguiar, João Pedro ; Alves da Costa, Filipa ; Egberts, Toine ; Leufkens, Hubert ; Souverein, Patrick</creatorcontrib><description>•APs with high affinity for Adrenergic alfa-1, Histaminic H1, Muscarinic M1, and Serotoninergic 5-HT2A were associated with a higher risk of reporting of MACCE compared to low affinity.•MACCE reporting rates might be related to those receptors antagonism as ziprasidone, olanzapine, and clozapine presented the highest RORs.•APs with higher-risk of MSE were associated with higher risk of reporting of MACCE compared to the lower-risk. Antipsychotics (APs) have been associated with major adverse cardio- and cerebrovascular events (MACCE), but the underlying mechanisms are unclear. Our aim was to elucidate the association between APs, stratified for receptor affinity and metabolic side effects (MSE), in the reporting of MACCE. A case/non-case study was conducted using data from the WHO global Individual Case Safety Report (ICSR) database, VigiBase, among all reports associated with an AP. Cases were ICSRs of MACCE, while non-cases were all other adverse drug reactions (ADRs). APs were classified by AP group, the degree of receptor affinity for adrenergic, dopaminergic, muscarinic, histaminic, and serotoninergic receptors and by MSE profile. The strength of the association was estimated with logistic regression and expressed as crude and adjusted reporting odds ratios (RORadj.) with corresponding 95% confidence intervals (95%CIs). We identified 4987 reports of MACCE and 328,907 reports of other ADRs. Atypical APs (RORadj. 2.46; 95%CI 2.20–2.74) were significantly associated with the reporting of MACCE compared to typical ones. APs with high affinity for Adrenergic alfa-1 (RORadj. 2.98; 95%CI 1.93–4.59), Histaminic H1 (RORadj. 2.31; 95%CI 1.98–2.68), Muscarinic M1 (RORadj. 1.87; 95%CI 1.74–2.01), and Serotoninergic 5-HT2A (RORadj. 3.19; 95%CI 2.07–4.92) were associated with a higher risk of reporting of MACCE compared to low affinity. APs with higher-risk of MSE were associated with higher risk of reporting of MACCE (RORadj. 1.88; 95%CI 1.73–2.05) compared to the lower-risk. APs with high affinity for Adrenergic alfa-1, Histaminic H1, Muscarinic M1, and Serotoninergic 5-HT2A receptors and with high-risk of MSE may explain the occurrence of those events.</description><identifier>ISSN: 0924-977X</identifier><identifier>EISSN: 1873-7862</identifier><identifier>DOI: 10.1016/j.euroneuro.2020.03.022</identifier><identifier>PMID: 32409260</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Antipsychotics ; Major adverse Cardio- and cerebrovascular events ; Pharmacoepidemiology ; Pharmacovigilance</subject><ispartof>European neuropsychopharmacology, 2020-06, Vol.35, p.30-38</ispartof><rights>2020</rights><rights>Copyright © 2020. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-dff7f3aaed0779e28106e6c7ec79d08481fa6cac96aa9cb5772d47623b4ea0ef3</citedby><cites>FETCH-LOGICAL-c420t-dff7f3aaed0779e28106e6c7ec79d08481fa6cac96aa9cb5772d47623b4ea0ef3</cites><orcidid>0000-0002-7452-0477 ; 0000-0003-1758-7779</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0924977X20300973$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32409260$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aguiar, João Pedro</creatorcontrib><creatorcontrib>Alves da Costa, Filipa</creatorcontrib><creatorcontrib>Egberts, Toine</creatorcontrib><creatorcontrib>Leufkens, Hubert</creatorcontrib><creatorcontrib>Souverein, Patrick</creatorcontrib><title>The association between receptor binding affinity and metabolic side effect profile of antipsychotics and major cardio- and cerebrovascular events: A case/non-case study using VigiBase</title><title>European neuropsychopharmacology</title><addtitle>Eur Neuropsychopharmacol</addtitle><description>•APs with high affinity for Adrenergic alfa-1, Histaminic H1, Muscarinic M1, and Serotoninergic 5-HT2A were associated with a higher risk of reporting of MACCE compared to low affinity.•MACCE reporting rates might be related to those receptors antagonism as ziprasidone, olanzapine, and clozapine presented the highest RORs.•APs with higher-risk of MSE were associated with higher risk of reporting of MACCE compared to the lower-risk. Antipsychotics (APs) have been associated with major adverse cardio- and cerebrovascular events (MACCE), but the underlying mechanisms are unclear. Our aim was to elucidate the association between APs, stratified for receptor affinity and metabolic side effects (MSE), in the reporting of MACCE. A case/non-case study was conducted using data from the WHO global Individual Case Safety Report (ICSR) database, VigiBase, among all reports associated with an AP. Cases were ICSRs of MACCE, while non-cases were all other adverse drug reactions (ADRs). APs were classified by AP group, the degree of receptor affinity for adrenergic, dopaminergic, muscarinic, histaminic, and serotoninergic receptors and by MSE profile. The strength of the association was estimated with logistic regression and expressed as crude and adjusted reporting odds ratios (RORadj.) with corresponding 95% confidence intervals (95%CIs). We identified 4987 reports of MACCE and 328,907 reports of other ADRs. Atypical APs (RORadj. 2.46; 95%CI 2.20–2.74) were significantly associated with the reporting of MACCE compared to typical ones. APs with high affinity for Adrenergic alfa-1 (RORadj. 2.98; 95%CI 1.93–4.59), Histaminic H1 (RORadj. 2.31; 95%CI 1.98–2.68), Muscarinic M1 (RORadj. 1.87; 95%CI 1.74–2.01), and Serotoninergic 5-HT2A (RORadj. 3.19; 95%CI 2.07–4.92) were associated with a higher risk of reporting of MACCE compared to low affinity. APs with higher-risk of MSE were associated with higher risk of reporting of MACCE (RORadj. 1.88; 95%CI 1.73–2.05) compared to the lower-risk. APs with high affinity for Adrenergic alfa-1, Histaminic H1, Muscarinic M1, and Serotoninergic 5-HT2A receptors and with high-risk of MSE may explain the occurrence of those events.</description><subject>Antipsychotics</subject><subject>Major adverse Cardio- and cerebrovascular events</subject><subject>Pharmacoepidemiology</subject><subject>Pharmacovigilance</subject><issn>0924-977X</issn><issn>1873-7862</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqFkVFvFCEQx4nR2Gv1KyiPvuyWhS3c-nY2ak2a-FKNb4SFoZ3LHpzAnrlv5seT9WpfDQlMht9_huFPyNuOtR3r5OW2hTnFsGwtZ5y1TLSM82dk1a2VaNRa8udkxQbeN4NSP87Iec5bxrorIYaX5Ezwvt5JtiK_7x6AmpyjRVMwBjpC-QUQaAIL-xITHTE4DPfUeI8By5Ga4OgOihnjhJZmdEDBe7CF7lP0OAGNvkIF9_loH2JBm08as63lrEkOY_M3YyHBmOLBZDtPJlE4QCj5Pd1UKsNliKFZAprL7I50zsszvuM9fqjJV-SFN1OG14_nBfn26ePd9U1z-_Xzl-vNbWN7zkrjvFdeGAOOKTUAX3dMgrQKrBocW_frzhtpjR2kMYMdr5TirleSi7EHw8CLC_LuVLcO93OGXPQOs4VpMgHinHX9ybqkYLKi6oTaFHNO4PU-4c6ko-6YXmzTW_1km15s00zoaltVvnlsMo87cE-6fz5VYHMCoI56QEg6W4RgwWE1qmgX8b9N_gBt87Nj</recordid><startdate>20200601</startdate><enddate>20200601</enddate><creator>Aguiar, João Pedro</creator><creator>Alves da Costa, Filipa</creator><creator>Egberts, Toine</creator><creator>Leufkens, Hubert</creator><creator>Souverein, Patrick</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7452-0477</orcidid><orcidid>https://orcid.org/0000-0003-1758-7779</orcidid></search><sort><creationdate>20200601</creationdate><title>The association between receptor binding affinity and metabolic side effect profile of antipsychotics and major cardio- and cerebrovascular events: A case/non-case study using VigiBase</title><author>Aguiar, João Pedro ; Alves da Costa, Filipa ; Egberts, Toine ; Leufkens, Hubert ; Souverein, Patrick</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-dff7f3aaed0779e28106e6c7ec79d08481fa6cac96aa9cb5772d47623b4ea0ef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antipsychotics</topic><topic>Major adverse Cardio- and cerebrovascular events</topic><topic>Pharmacoepidemiology</topic><topic>Pharmacovigilance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aguiar, João Pedro</creatorcontrib><creatorcontrib>Alves da Costa, Filipa</creatorcontrib><creatorcontrib>Egberts, Toine</creatorcontrib><creatorcontrib>Leufkens, Hubert</creatorcontrib><creatorcontrib>Souverein, Patrick</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European neuropsychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aguiar, João Pedro</au><au>Alves da Costa, Filipa</au><au>Egberts, Toine</au><au>Leufkens, Hubert</au><au>Souverein, Patrick</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The association between receptor binding affinity and metabolic side effect profile of antipsychotics and major cardio- and cerebrovascular events: A case/non-case study using VigiBase</atitle><jtitle>European neuropsychopharmacology</jtitle><addtitle>Eur Neuropsychopharmacol</addtitle><date>2020-06-01</date><risdate>2020</risdate><volume>35</volume><spage>30</spage><epage>38</epage><pages>30-38</pages><issn>0924-977X</issn><eissn>1873-7862</eissn><abstract>•APs with high affinity for Adrenergic alfa-1, Histaminic H1, Muscarinic M1, and Serotoninergic 5-HT2A were associated with a higher risk of reporting of MACCE compared to low affinity.•MACCE reporting rates might be related to those receptors antagonism as ziprasidone, olanzapine, and clozapine presented the highest RORs.•APs with higher-risk of MSE were associated with higher risk of reporting of MACCE compared to the lower-risk. Antipsychotics (APs) have been associated with major adverse cardio- and cerebrovascular events (MACCE), but the underlying mechanisms are unclear. Our aim was to elucidate the association between APs, stratified for receptor affinity and metabolic side effects (MSE), in the reporting of MACCE. A case/non-case study was conducted using data from the WHO global Individual Case Safety Report (ICSR) database, VigiBase, among all reports associated with an AP. Cases were ICSRs of MACCE, while non-cases were all other adverse drug reactions (ADRs). APs were classified by AP group, the degree of receptor affinity for adrenergic, dopaminergic, muscarinic, histaminic, and serotoninergic receptors and by MSE profile. The strength of the association was estimated with logistic regression and expressed as crude and adjusted reporting odds ratios (RORadj.) with corresponding 95% confidence intervals (95%CIs). We identified 4987 reports of MACCE and 328,907 reports of other ADRs. Atypical APs (RORadj. 2.46; 95%CI 2.20–2.74) were significantly associated with the reporting of MACCE compared to typical ones. APs with high affinity for Adrenergic alfa-1 (RORadj. 2.98; 95%CI 1.93–4.59), Histaminic H1 (RORadj. 2.31; 95%CI 1.98–2.68), Muscarinic M1 (RORadj. 1.87; 95%CI 1.74–2.01), and Serotoninergic 5-HT2A (RORadj. 3.19; 95%CI 2.07–4.92) were associated with a higher risk of reporting of MACCE compared to low affinity. APs with higher-risk of MSE were associated with higher risk of reporting of MACCE (RORadj. 1.88; 95%CI 1.73–2.05) compared to the lower-risk. APs with high affinity for Adrenergic alfa-1, Histaminic H1, Muscarinic M1, and Serotoninergic 5-HT2A receptors and with high-risk of MSE may explain the occurrence of those events.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>32409260</pmid><doi>10.1016/j.euroneuro.2020.03.022</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-7452-0477</orcidid><orcidid>https://orcid.org/0000-0003-1758-7779</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0924-977X
ispartof European neuropsychopharmacology, 2020-06, Vol.35, p.30-38
issn 0924-977X
1873-7862
language eng
recordid cdi_proquest_miscellaneous_2404046306
source Elsevier ScienceDirect Journals
subjects Antipsychotics
Major adverse Cardio- and cerebrovascular events
Pharmacoepidemiology
Pharmacovigilance
title The association between receptor binding affinity and metabolic side effect profile of antipsychotics and major cardio- and cerebrovascular events: A case/non-case study using VigiBase
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T01%3A31%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20association%20between%20receptor%20binding%20affinity%20and%20metabolic%20side%20effect%20profile%20of%20antipsychotics%20and%20major%20cardio-%20and%20cerebrovascular%20events:%20A%20case/non-case%20study%20using%20VigiBase&rft.jtitle=European%20neuropsychopharmacology&rft.au=Aguiar,%20Jo%C3%A3o%20Pedro&rft.date=2020-06-01&rft.volume=35&rft.spage=30&rft.epage=38&rft.pages=30-38&rft.issn=0924-977X&rft.eissn=1873-7862&rft_id=info:doi/10.1016/j.euroneuro.2020.03.022&rft_dat=%3Cproquest_cross%3E2404046306%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2404046306&rft_id=info:pmid/32409260&rft_els_id=S0924977X20300973&rfr_iscdi=true